Carter Charles Ross 4
4 · CERO THERAPEUTICS HOLDINGS, INC. · Filed Jul 1, 2024
Insider Transaction Report
Form 4
Carter Charles Ross
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-06-28+100,000→ 100,000 totalExercise: $0.30Exp: 2034-06-28→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]All of the shares underlying this option will vest on the date of the acceptance of an Investigational New Drug application by the U.S. Food and Drug Administration, subject to the Reporting Person's continued service on such vesting date.